C2i Genomics and NovogeneAIT Genomics Partner to Bring AI-Powered Cancer Detection to South East Asia
This partnership will bring 100x more sensitive cancer detection and treatment management to sequencing labs across South East Asia
NEW YORK — June 10, 2021 — C2i Genomics, a cancer intelligence company, today announced it has signed a collaboration partnership agreement with NovogeneAIT Genomics, a leading global provider of genomic services and solutions. This partnership begins the global commercial launch of the C2-Intelligence Platform, a cancer diagnostics service that uses AI pattern recognition and whole-genome analysis to provide rapid and accurate detection of residual disease that is up to 100x more sensitive than competing technologies.
The partnership will deploy the C2-Intelligence Platform to NovogeneAIT’s sequencing labs in South East Asia. This will allow physicians to spot tiny traces of persistent or recurrent cancer much earlier, and at far lower levels than currently available, driving better treatment decisions, and ultimately saving lives.
C2i’s platform includes whole-genome tumor profiling for increased diagnostic yield; and tumor-informed blood-based MRD testing for cancer burden monitoring and personalized treatment management. In addition, C2i reports the development and initial validation of a blood-only test capable of detecting cancer and monitoring the tumor burden and tumor mutation burden (bTMB) from routine low-input blood samples, without the need for matched tumor tissue.
“NovogeneAIT’s expertise and scale makes them the perfect partner to bring the C2i technology to South East Asia, and we are excited and eager to initiate this important collaboration,” said Asaf Zviran, co-founder and CEO of C2i Genomics. “Every patient worldwide deserves to get the best cancer care with state-of-the-art and personalized treatment management. This agreement is the first step in C2i’s commitment to provide global and uniform accessibility to our life-saving technology.”
NovogeneAIT labs offer state-of-the-art next-generation sequencing technology and the largest sequencing capacity in the region, which is perfectly suited for C2i’s cloud-based GDPR and HIPAA compliant platform. The company will work with C2i and serve as a reference lab to carry this rapid and accurate residual disease test to South East Asia markets. The company will also be granted a non-exclusive right to distribute and market C2i’s pharmaceutical and diagnostic services in the region.
“We’re thrilled to offer C2i’s breakthrough cancer diagnostics platform to our customers across South East Asia,” said Justin Lee, CEO of NovogeneAIT Genomics. “By providing more sensitive and accurate cancer detection, we believe this partnership will see meaningful results for patients across the region.”
The C2i Intelligence Platform is already being used for both clinical research and drug development in multiple locations around the world, including the National Cancer Centre Singapore (NCCS), Aarhus University Hospital, NYU Langone Health, Lausanne University Hospital (CHUV), and others. The announcement comes shortly after C2i secured over $100M in financing led by Casdin Capital to help accelerate clinical development and commercialization of its services. C2i plans to continue this mission and expand its global reach in the near future.
About C2i Genomics
Founded in 2019, C2i Genomics has created the world’s leading cancer treatment intelligence platform that uses low-input blood (only 2mL blood) whole-genome sequencing to provide up to 100x more sensitive detection than competing liquid biopsy companies. With a headquarters in NYC, CLIA lab in Cambridge MA, and an R&D center in Israel, C2i’s SaaS solution utilizes a cloud-based platform to perform cancer tumor burden monitoring on a global scale, leveraging the thousands of already installed genome sequencers around the world. Using cutting-edge scientific breakthroughs, growing genomic and clinical databases, and sophisticated computation and AI, C2i enables high precision personalized medicine, reduced cancer treatment costs, and accelerated drug development. For more information, please visit www.c2i-genomics.com.
About NovogeneAIT Genomics
NovogeneAIT Genomics delivers unsurpassed data quality to support our customers’ research goals. NovogeneAIT is a joint venture between Novogene and AIT Biotech focusing in the South East Asia region. Being the world leader in Next Generation Sequencing (NGS) services, Novogene has strong scientific expertise and experience with 36 NGS-related patents and over 600 research papers with total impact factors at more than 4270, including publications in first-tier journals such as Cell, Nature and Science. As the largest NGS service provider headquartered in Beijing with branches in Hong Kong China, US, UK, Singapore, Netherlands and Japan, Novogene was founded in 2011 and has been growing rapidly over the past decade. Novogene has global genomic sequencing labs in the US (at The University of California at Davis campus), China, Singapore, and the UK (Cambridge). To learn more, visit novogene.com/us-en.